Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Woodline Partners LP

Woodline Partners LP lifted its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 24.8% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 582,327 shares of the company's stock after purchasing an additional 115,809 shares during the quarter. Woodline Partners LP owned about 0.98% of Protagonist Therapeutics worth $22,478,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Barclays PLC raised its position in Protagonist Therapeutics by 223.6% in the third quarter. Barclays PLC now owns 126,995 shares of the company's stock valued at $5,714,000 after purchasing an additional 87,755 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at about $2,016,000. Nisa Investment Advisors LLC raised its holdings in shares of Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after buying an additional 295 shares during the period. KBC Group NV lifted its position in Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after acquiring an additional 737 shares in the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in Protagonist Therapeutics by 8.2% in the 4th quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock worth $72,432,000 after acquiring an additional 142,376 shares during the period. Institutional investors and hedge funds own 98.63% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on PTGX. BTIG Research set a $73.00 target price on shares of Protagonist Therapeutics in a research report on Monday, March 3rd. JMP Securities reaffirmed a "market outperform" rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research note on Friday, February 7th. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a research report on Monday, May 19th. The Goldman Sachs Group cut their price target on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, February 24th. Finally, JPMorgan Chase & Co. raised their price objective on Protagonist Therapeutics from $53.00 to $57.00 and gave the company an "overweight" rating in a research note on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $65.44.

Insider Transactions at Protagonist Therapeutics

In other Protagonist Therapeutics news, Director William D. Waddill sold 4,000 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the sale, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This trade represents a 23.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Asif Ali sold 1,756 shares of the business's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $46.00, for a total transaction of $80,776.00. Following the transaction, the chief financial officer now directly owns 61,065 shares of the company's stock, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 61,173 shares of company stock worth $3,461,180. 4.90% of the stock is currently owned by insiders.

Protagonist Therapeutics Trading Down 0.5%

Protagonist Therapeutics stock traded down $0.25 during midday trading on Monday, hitting $45.66. The stock had a trading volume of 486,198 shares, compared to its average volume of 881,795. The business has a fifty day moving average price of $45.86 and a 200 day moving average price of $42.53. Protagonist Therapeutics, Inc. has a 12 month low of $27.00 and a 12 month high of $60.60. The stock has a market cap of $2.83 billion, a P/E ratio of 17.17 and a beta of 2.65.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.31. The business had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. On average, equities analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.